#ApexOnco

BeiGene bows out of TIGIT AstraZeneca and GSK/iTeos's odysseys get a little lonelier still.

Bye-Bei TIGIT - a lesson in the dangers of mediocre science butting up against the challenges of complex ligand/receptor interactions, FcReceptor biology, and cancer resistance mechanisms

Beigene news via #ApexOnco

www.oncologypipeline.com/apexonco/bei...